Brandon Anjuwon-Foster

Brandon R. Anjuwon-Foster, Ph.D. is a Pharmaceutical Scientist in CDER's Office of Product Quality Assessment III (OPQAIII) of the FDA, where he protects and advances the public health through assessment and regulation of pharmaceutical quality in biologic products (e.g., monoclonal antibodies, insulins, fusion proteins, enzymes, etc.). He previously worked in CDRH's Division of Microbiology Devices as a Microbiologist for 2.5 years conducting regulatory review of in vitro diagnostic devices. Prior to joining the federal service, he worked at PPD (now part of Thermo Fisher Scientific) as a principal investigator leading a team to optimize and validate a functional bioassay used to measure vaccine-induced functional antibodies against Neisseria meningitidis for future clinical trial testing. Dr. Anjuwon-Foster earned a B.S. in Neuroscience from George Mason University, a Ph.D. in Microbiology & Immunology from the University of North Carolina at Chapel Hill and completed a postdoctoral fellowship at the National Cancer Institute.